American Oncology Network, Inc. reported a 20.0% increase in revenue to $364.3 million for the first quarter of 2024, driven by a 7.1% growth in patient encounters and strategic acquisitions. The company's net loss before non-controlling interest was $24.9 million, and Adjusted EBITDA was $2.0 million.
Revenue increased by 20.0% to $364.3 million compared to the prior year quarter.
Patient encounters grew by 7.1% compared to the prior year quarter.
17 new providers were added to the AON platform, expanding in Texas and Maryland markets.
Net cash provided by operating activities was $45.1 million, driven by the deferral of $48.3 million of drug payments due to the Change Healthcare issue.
AONC did not provide specific forward guidance in this earnings report. The report focuses on Q1 2024 results and strategic initiatives.
Visualization of income flow from segment revenue to net income